Circuitcity, Thero has not dealt effectively with generic Lovaza which
is a very inexpensive omega-3 product and the one that insurance copanies
want to push instead of Vascepa or even generic Vascepa, because of its
low cost. Thero does not have the gravitas to make Vascepa great.
Why would AMRN seriously consider building its own sales force in Europe
when their are established BP with successful sales reps who already have
all important relationships with prescribers there? A partnership
arrangement would be stupid as Thero has proven to us with his costly
and useless partnership with Kowa. Hopefully, Thero and his BOD will
not repeat the same mistakes over and over again.
Unless Thero is working on a BO strategy right now, he should be removed
by the BOD as CEO. If the intent is to GIA AMRN needs new leadership. I
still believe a BO is likely to happen because it is the most rational
way to proceed, especially to optimize the value for Europe. Selling
AMRN to BP would get a life saving medication into the hands of CVD
patients much faster and in far bigger numbers than a Thero led GIA
approach. AMRN IR recently stated it cannot address the takeover
prospect of AMRN for "legal reasons." My hope is that it means they
may be in exclusive discussions with someone.
News 
Market Data 
Discover 
AI
